- A New Medicare Option for Weight Loss Drugs: What Older Americans Should Know
- Trump’s Drug Strategy Aims To Bolster Addiction Services — Despite Gutting of Government Support
- Rethinking DSOs: Challenging common misconceptions in modern dentistry
- WakeMed CEO says years of talks led to Atrium deal: ‘We’re the smallest health system of the competitive world now in North Carolina’
- 9 behavioral health facility and service closures, layoffs in 2026
- The new class of opioids: 4 things to know
- Maine health system unveils unified brand
- Physicians in Congress propose Medicare payment overhaul
- 2 men sentenced in $522M fraud, kickback scheme
- What 3 ASC leaders are saying about cardiology’s race to outpatient
- Hospital at home linked to better outcomes: 7 notes
- Long-established Florida physician practice acquired
- Facilitating Access to Trump Accounts
- HCA Tennessee hospital taps COO
- WellSpan Health to open 4-room ASC in Pennsylvania
- Colorado hospital names new CEO
- Yale New Haven hospital president to retire
- Ascension Tennessee hospital names COO
- Nurses fret AI overreliance could erode care, call for more guardrails
- ‘Dynamics we haven’t experienced before’: Hospitals absorb costs as patients lose coverage, skip Medicaid
- Fatality risk grows 8% per added med-surg nurse patient: Study
- Surgery Partners increases same-facility revenue by 4% in Q1: 10 notes
- Fixing Failures to Communicate
- Dr. Nisha D’Silva installed as president of the American Association for Dental, Oral and Craniofacial Research
- PDS Health, CareQuest partner to expand blood pressure screenings in dental offices
- 5 hospitals, health systems investing in ASCs
- Bankruptcy, PE debt and a $3.9B Ascension deal: A 30-year breakdown of AmSurg
- Henry Schein increases global dental sales by 9% in Q1: 7 notes
- Heartland Dental expands in 7 states
- Ohio woman charged with practicing unlicensed dentistry
- 15 physician deals in 40 days
- Psych hospital eases security tool restrictions after violent incidents
- For nonprofit hospitals, pricey management consultants haven't yielded better performances: study
- TriHealth hospital hit with $10M verdict in psychiatric unit death
- Supreme Court Issues Stay, Keeping Abortion Pill Mifepristone Available by Mail For Now
- From 1st-in-state to 1st-in-world: 5 surgical milestones to know
- 3 dental mergers, acquisitions in April
- Statement on Proposing Release for Semiannual Reporting
- Quarterly Questions: Statement on the Proposed Amendments to Allow Semiannual Reporting
- HHS outlines plan to ‘curb psychiatric overprescribing’: 5 things to know
- Former Oklahoma dental assistant sentenced to prison for assaulting patients
- Statement on Proposing Semiannual Reporting
- Transforming Behavioral Healthcare Delivery through the Collaborative Care Model
- Wellstar partners with BD to implement AI-driven medication management system
- Tennessee dental practice to close due to financial strain
- Listen to the Latest ‘KFF Health News Minute’
- Lifepoint Health taps new vice president of finance from Acadia
- UnitedHealthcare to reduce prior auth requirements by 30%
- ‘Retire one-and-done interventions’: Wellstar achieves 40% drop in physician distress
- Newer Migraine Drugs Reduce Headache Days With Fewer Side Effects
- Pfizer delivers strong Q1 but keeps guidance steady amid COVID seasonality
- CVS to expand biosimilar formulary adoptions to improve affordability, accessibility
- New Drug Combo Effective Against Treatment-Resistant IBD, Trials Show
- New Warning Labels Might Help People Cut Back On Drinking
- Novartis to close German manufacturing site, cutting 220 jobs
- BioNTech to slash 1,860 jobs, exit sites in Germany and Singapore in major manufacturing pullback
- After Alzheimer's agitation nod, Axsome jacks up Auvelity's peak sales projection to $8B
- Ozempic Can Curb Cravings in Alcohol Use Disorder, Landmark Trial Finds
- US on the Brink of Losing Measles-free Status, Study Warns
- Delays in Visa Program Threaten Doctor Placements in Underserved Areas
- Sanofi expands AI capabilities, investing $294M to scale Toronto hub
- States Eye Aid To Prop Up Distressed Hospitals Amid Federal Medicaid Cuts
- Assort Health rolls out outbound AI agent for personalized patient outreach
- Neurocrine cites work disruption data to make case for timely movement disorder diagnosis
- Eyeing CAR-T autoimmune first, Kyverna hires pharma veteran as CCO
- Newly formed Keenova launches ‘Don't Be a Viking’ campaign for Dupuytren’s contracture
- Supreme Court Puts Brakes on Abortion Pill Restrictions
- Cytokinetics' Myqorzo succeeds in landmark cardiomyopathy trial
- Why state dental boards are scrutinizing DSOs
- Child Mind Institute names chief clinical officer
- UMass Memorial behavioral health provider to lay off 78 employees
- Prolific Machines sets monoclonal antibody manufacturing record with light-controlled platform
- Healthcare Dealmakers—UConn Health grows, Centene subsidiaries merge and more
- FDA Green Lights Expanded Access to Pancreatic Cancer Drug, Daraxonrasib
- American Hospital Association, West Health Institute partner to help health systems scale new tech
- Alignment CEO expects short delay for CMS' proposed risk adjustment changes
- WakeMed Health's plans to join Atrium Health face swift pushback from NC officials
- Online Misinformation Adding To Americans' Skin Cancer Risk, Survey Finds
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Medtronic’s Updated Mitral Valve, Mosaic Neo, Gets FDA approval
- Social Media Videos, Easy Access Raise Risk of Teen Inhalant Use
- Staff Statement Regarding Pooled Employer Plans
- SCOTUS temporarily restores online access to abortion pill after appeals court ruling
- SCOTUS temporarily restores online access to abortion pill after appeals court ruling
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Sonire Therapeutics Initiates First U.S. Clinical Study of Ultrasound-Guided HIFU Therapy for Pancreatic Cancer
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Edwards Lifesciences Shares Ten-Year Pivotal Data Supporting Long-Term Durability of Resilia Tissue
- Nearly half of reproductive age women with Medicaid coverage live in states restricting abortion: KFF
- 'Fitspirational' Posts Can Be More Harmful Than Motivational, Review Concludes
- CDMO Samsung Biologics estimates $102M impact stemming from ongoing union strike
- After March cuts, Novartis trims another 60 roles at US headquarters
- Parents’ Stress Tied to Children’s Mental Health, New Survey Finds
- Surgeon Multitasking Increases Death Risk Of Organ Transplantees
- Bristol Myers Squibb ties science to soccer in World Cup campaign voiced by Ali Krieger
- When Natural Disasters Strike, Another Crisis Hits Those Recovering From Opioid Addiction
- HHS’ Healthy Food Agenda Puts Hospitals on Notice About Patients’ Meals
- She Survived 2 Shootings. Research Helps Explain Why Her Pain Persists Years Later.
- Amgen channels another $300M into US outlay, bolstering Puerto Rico biologics expansion
- Journalists Share Latest on Baby Formula Safety, Estrogen Patches, and Postcancer Costs
- Prevention Efforts Increasingly See Suicide Through a Broader Lens
- FDA Recalls Several Ghirardelli Powdered Beverages Over Potential Contamination
- FDA hands Pfizer, Arvinas’ Veppanu early approval for breast cancer subtype
- High-Intensity Exercise After Breast Cancer Surgery Helps Speed Recovery
- Trump Offers Third Candidate For Surgeon General After Pulling Dr. Casey Means' Nomination
- Industry Voices—Value-based care won the policy argument. Now it has to deliver
- Senators introduce clean extension to cost-based payments for some rural hospitals
- Beth Israel Lahey Health taps Heidi for system-wide AI scribe rollout
- Johnson & Johnson Enters Agreement to Acquire Atraverse Medical
- Johnson & Johnson Enters Agreement to Acquire Atraverse Medical
- enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve
- enVVeno Medical Receives FDA IDE Approval for Non-Surgical Replacement Venous Valve
- Medtronic Gains CE Mark for Stealth AXiS surgical system
- Medtronic Gains CE Mark for Stealth AXiS surgical system
- Medtronic Continues Cardiovascular Care Growth with Completion of CathWorks Acquisition
- Medtronic Continues Cardiovascular Care Growth with Completion of CathWorks Acquisition
- Cleveland Clinic taps startup Luminai to test how AI can run hospital operations
- Look out Rexulti, Axsome's Auvelity has its nod for Alzheimer's agitation
- Cardio drug developer Esperion to go private in potential $1.1B buyout by ArchiMed
- Union workers at Korean CDMO Samsung Biologics kick off strike
- Summit's PD-1xVEGF interim trial miss surprises analysts, shares tumble
- Health Tech Weekly Rundown: Sage launches Tasking for senior care workflows; St. Luke’s taps Auxira Health for cardiologist support
- Confusion Continues Over Age To Start Breast Cancer Screening, Survey Finds
- Senses, Not Muscles, Key to Speech Recovery After Stroke
- Antibiotics Not Linked To Celiac Disease Risk, Study Argues
- Common Knee Surgery Doesn't Help, Might Actually Make Things Worse, Clinical Trial Reports
- States Rush To Figure Out How To Enforce Trump's Medicaid Work Requirements
- Gavin Newsom, Early Champion of Single-Payer, Moderates in the Face of Fiscal Limits
- Delays in Visa Program Threaten Placement of Hundreds of Doctors in Underserved Areas
- FDA Permits Expanded Access for Investigational Pancreatic Cancer Drug Daraxonrasib
- From Prototype to Production: Building a Validation Strategy That Scales with Manufacturing Volume
- From Prototype to Production: Building a Validation Strategy That Scales with Manufacturing Volume
- Managing AI in Medical Technology: From Innovation to Compliance
- Managing AI in Medical Technology: From Innovation to Compliance
- Seven Things Every Medical Device Manufacturer Must Know Before Integrating AI
- Seven Things Every Medical Device Manufacturer Must Know Before Integrating AI
- New Medical Guidelines Urge More Fiber, Less Bathroom Scrolling on Your Phone
- Sleep and Anxiety Medications in Pregnancy Appear to Pose Little Harm
- Trump's Medicaid Work Mandate Debuting in Nebraska to Much Dismay
- Nasal Spray Flu Vaccines Create 'Battlefield' In Adults' Noses
- Prehabilitation Slashes Post-Op Complications By Half, Review Says
- Understanding Emotions Could Be Key To Quelling Chronic Pain
- Meth Caused 1 In 6 Heart Attacks Over A Decade, Study Finds
- Rising Stars: Axplora’s Arsalan Khan gets technical on marketing
- Orchestrating Affordability: The Critical New Role of the Health Plan
- The Case for a More Proactive Payment Integrity Program
- AI Tool May Help Identify ADHD in Kids Long Before Typical Diagnosis
- FDA Moves to Real-Time Clinical Trial Patient Monitoring, Faster Drug Review
- Dementia Screening Safe For Families, Trial Finds
- Online Program Soothes Post-Trauma Stress In Injured Children
Dr. Jay Bhattacharya provided more details on the planned National Institutes of Health (NIH) scientific journal which will publish science which has been replicated. This will go a long way in exposing today's shoddy and fraudulent science research:
https://www.zerohedge.com/political/nih-director-gives-more-details-new-government-medical-journal
NIH Director Gives More Details On New Government Medical Journal
By Zachary Stieber of The Epoch Times - June 11, 2025The National Institutes of Health (NIH) will start a new journal that will help change the culture of science, the agency’s director said in a newly released interview.
“The NIH can stand up and will stand up a journal where these replication results can be published and made searchable in an easy way,” Dr. Jay Bhattacharya said in a four-hour podcast interview with Andrew Huberman, a professor at the Stanford University School of Medicine, released on June 9.
Bhattacharya said he envisions people being able to see summaries of similar papers that looked at the same questions.
“A scientific journal put out by the NIH, a high-profile journal will then make publishing replication work a high-profile scientific, high-prestige scientific activity,” he added later.
Health Secretary Robert F. Kennedy Jr. said in May that federal scientists would likely be told to stop publishing in medical journals and, if that happened, the NIH would launch journals that would publish the scientists’ research.
Kennedy said that the existing journals have problems such as not publishing all of the data that underpins studies, while Bhattacharya said the journals will not publish replication research. Both officials have said they want the government to devote resources to replication, with Kennedy estimating that 20 percent of the NIH budget be designated for that purpose.
Replication is the process of taking a study, repeating it, and seeing if the results are the same.
While some scientists conduct meta-analyses, or studies that sum up existing literature on a topic—which could be considered a form of replication—“it’s really difficult to make a career out of doing replication work as a general matter,” Bhattacharya said in the podcast.
Scientists cannot at present earn large grants from the NIH for such work, which means the scientists cannot receive tenure at a top university, he said. That dissuades young scientists from focusing on replication work.
“We don’t reward it. The NIH doesn’t reward it,” Bhattacharya said. “That will change.”
The new journal will also publish negative results, or when scientists try to replicate a study and fail.
Emphasizing replication will make scientific literature more reliable, according to Bhattacharya, including for drug discovery and individual behavior, and will change the culture of science so that it “rewards truth ... rather than influence,” he added later.
Huberman, a neuroscientist, said that he welcomed the new journal and the focus on replication. “Everything you’re saying is very reassuring, and should be reassuring to people,” he said. “It’s music to my ears, frankly.”
The interview was released the same day some NIH employees signed a declaration that called cuts to NIH grants harmful and urged Bhattacharya to restore them. The NIH has terminated more than 2,000 grants totaling some $9.5 billion, as well as $2.6 billion in contracts, the employees said. The Trump administration is also proposing a smaller budget for the NIH in the next fiscal year.
Huberman noted that some grants that were labeled as diversity, equity, and inclusion (DEI) were cut and questioned Bhattacharya on whether the cuts included grants with the word transgenic. Bhattacharya said that there’s been an appeal process set up and researchers whose grants should not have been cut can file with the government. Some grants that were cut have been restored.
The NIH director said that it’s important to carry out research on vulnerable populations, and there are legitimate scientific questions where race or sex matters, such as breast cancer.
“The NIH absolutely supports that kind of research still despite all of the changes,” he said.
Bhattacharya also said that DEI is centered on the idea that structural racism is primarily responsible for the health outcomes of minorities and that he could not think of a scientific experiment that would in principle falsify that idea. Researchers who want to conduct studies based on the idea will not receive funding, he indicated.
“Let’s focus on the mission,” Bhattacharya said. “The mission is how do we advance, how do we make investments in research that advance the health and longevity of the American people ... I don’t believe there’s any place for this sort of race essentialism in it.”
Speaking of fraudulent research:
[A] paper, published today in the Proceedings of the National Academy of Sciences, paints an alarming picture. Northwestern University metascientist Reese Richardson and his colleagues identify networks of editors and authors colluding to publish shoddy or fraudulent papers, report that large organizations are placing batches of fake papers in journals, suggest brokers may serve as intermediaries between paper mills and intercepted journals, and find that the number of fake papers—though still relatively small—seems to be increasing at a rate far greater than the scientific literature generally.
https://www.science.org/content/article/scientific-fraud-has-become-industry-alarming-analysis-finds
Scientific fraud has become an ‘industry,’ alarming analysis finds
Sophisticated global networks are infiltrating journals to publish fake papers
By Cathleen O’Grady - o4 August 2025For years, sleuths who study scientific fraud have been sounding the alarm about the sheer size and sophistication of the industry that churns out fake publications. Now, an extensive investigation finds evidence of a range of bad actors profiting from fraud. The study, based on an analysis of thousands of publications and their authors and editors, shows paper mills are just part of a complex, interconnected system that includes publishers, journals, and brokers.
The paper, published today in the Proceedings of the National Academy of Sciences, paints an alarming picture. Northwestern University metascientist Reese Richardson and his colleagues identify networks of editors and authors colluding to publish shoddy or fraudulent papers, report that large organizations are placing batches of fake papers in journals, suggest brokers may serve as intermediaries between paper mills and intercepted journals, and find that the number of fake papers—though still relatively small—seems to be increasing at a rate far greater than the scientific literature generally.
The paper shows that misconduct “has become an industry,” says Anna Abalkina of the Free University of Berlin, who studies corruption in science and was not involved with the research. Richardson and colleagues hope their sweeping case will attract attention and spur change.
They began their analysis by pinpointing corrupt editors. They focused their investigation on PLOS ONE, because the megajournal allows easy access to bulk metadata and publishes the names of the editors who have handled the thousands of papers it publishes each year, making it possible to detect anomalies without behind-the-scenes information. The researchers identified all the papers from the journal that had been retracted or received comments on PubPeer—a website that allows researchers to critique published work—and then identified each paper’s editors.
All told, 33 editors stood out as more frequently handling work that was later retracted or criticized than would be expected by chance. “Some of these were immense outliers,” Richardson says. For instance, of the 79 papers that one editor had handled at PLOS ONE, 49 have been retracted. Flagged editors handled 1.3% of papers published in the journal by 2024, but nearly one-third of all retracted papers.
The team also spotted that these editors worked on certain authors’ papers at a suspiciously high rate. These authors were often editors at PLOS ONE themselves, and they often handled each other’s papers. It’s possible that some editors are being paid bribes, Richardson says, but “also possible that these are informal arrangements that are being made among colleagues.” The researchers detected similarly questionable editor behavior in 10 journals published by Hindawi, an open-access publisher that was shuttered because of rampant paper mill activity after Wiley acquired it. A spokesperson for Wiley told Science the publisher has made “significant investments to address research integrity issues.”
Renee Hoch, head of publication ethics at PLOS, said in an email to Science that the publisher has long been aware of networks like these, and will assess whether any of the editors implicated are still on the journal’s editorial board, opening investigations if they are. She emphasizes that the study focused on PLOS because of its readily accessible data: “Paper mills are truly an industry-wide problem.”
Researchers working on paper mills have long assumed that editors and authors have been colluding. The new findings are “killer evidence” for these suspicions, says Domingo Docampo, a bibliometrician at the University of Vigo. He adds that although the findings only show collusion at a limited number of journals, others are probably affected. Just last week, Retraction Watch reported that the publisher Frontiers had begun to retract 122 papers after discovering a network of editors and authors “who conducted peer review with undisclosed conflicts of interest,” according to a company statement. The network of 35 individuals has also published more than 4000 papers in journals from seven other publishers, the company said, which require further scrutiny. A Frontiers spokesperson said they planned to share information with the other affected publishers.
Richardson and his colleagues found that the problem goes far beyond networks of unscrupulous editors and authors scratching each other’s backs. They identified what appear to be coordinated efforts to arrange the publication of batches of dubious papers in multiple journals.
The team looked at more than 2000 papers flagged on PubPeer for containing duplicated images and identified clusters of papers that all shared images. Those sets of papers were often published around the same time and in a limited selection of journals. Looking at patterns of duplicated images is an “absolutely innovative” method for investigating these networks, Abalkina says. “No-one has done this before.”
In some cases, the authors suggest, a single paper mill that infiltrated multiple journals may be responsible. But they also believe some of these clusters reflect the work of “brokers” who act as go-betweens, taking papers produced by mills and placing them at compromised journals.
The team dug into the workings of the Academic Research and Development Association (ARDA), based in Chennai, India, which offers services including “thesis/article writing” as well as “journal publication” in a list of dozens of journals. On a web page listing “high impact journals” on offer, ARDA says that it liaises with journals on behalf of researchers and “[ensures] they get published successfully in the High Impact Indexing Database journal of their choice.”
Over several years, ARDA’s list of journals has evolved, the team found, with new publications added to the list and others removed after being delisted by bibliometric databases because of fishy behavior. The journals often publish transparently “problematic” articles, Richardson says, and ARDA charges between $250 and $500 for publication, based on quotes offered to Richardson and his colleagues. The website asks authors to submit their own papers, suggesting ARDA itself is not a paper mill, but rather a go-between, Richardson says.
ARDA did not respond to a request for comment.
Organizations like these operate in broad daylight, under the guise of providing “editorial services,” says Lokman Meho, an information scientist at the American University of Beirut. Although their operations may be unethical—with stark consequences for science and scientists—they don’t care about trying to hide, he says, because “it is actually not illegal to run such businesses.”
The problems Richardson and his colleagues documented are growing fast. The team built a list of papers identified in 55 databases of likely paper mill products, looking at the number of suspicious papers published each year between 2016 and 2020. (They excluded the past few years of data because it takes time for fraudulent papers to be discovered and retracted.) They found that the number of suspected paper mill products doubled every 1.5 years—10 times faster than the rate of growth of the literature as a whole, although still a small proportion of papers overall. The number of retractions and papers flagged on PubPeer had also risen fast, doubling every 3.3 and 3.6 years, respectively, but not keeping pace with the increase in suspected fraudulent papers. “This means that the percentage of fraudulent science is growing,” Abalkina says. That poses particular risks to fields like medical science, where the fake papers sometimes make their way into systematic reviews and meta-analyses, potentially distorting our understanding of drugs and treatments, she says.
One contributor is the rapid growth of science, says Wolfgang Kaltenbrunner, a science studies scholar at Leiden University. Paper mill products are often buried in low-impact journals and are written to get little attention, he says. In small scientific communities, it is harder to hide products like these, but as some fields get larger and more anonymous, such papers can escape detection more easily. And as the scientific workforce has burgeoned, institutions have increasingly turned to evaluating scientists based on how many publications they produce, leading some researchers to bolster their records with fake papers, he says. “Perverse incentives, inflated metrics, the ‘publish or perish’ culture, and systemic tolerance for weak scholarship” all allow paper mills to flourish, says Li Tang, an expert on Chinese research policy at Fudan University.
Young researchers may feel forced into paying for paper mill publications to compete with peers—a ratcheting effect that is already apparent, Richardson says. The number of papers published by medical residency applicants has soared in recent years, for instance, with some students claiming authorship of dozens of papers. He says it’s no coincidence that the paper mill industry targets residency applicants, especially foreign students on visas.
Docampo, Abalkina, and others say there’s little in the new paper that wasn’t already strongly suspected. But the dramatic confirmation that the study offers may shift the needle, they say. “We’re massively behind the curve on making visible and realizing the extent of the problem,” Kaltenbrunner says. “The sheer scale of it is the takeaway message here.”
And unless publishers, funders, and people in charge of hiring and promotion pay attention and penalize this behavior, Docampo says, “it will continue. It’s growing fast.”
Believe the Science, maybe? 😮
More on the paper mills' discovery:
A Massive Fraud Ring Is Publishing Thousands of Fake Studies and the Problem is Exploding. “These Networks Are Essentially Criminal Organizations”
Organized misconduct is rapidly poisoning the global scientific record.
By Tibi Puiu - August 6, 2025One awful spring day in 2025, Luís Amaral sat at his desk at Northwestern University after he had just finished “probably the most depressing project I’ve been involved with.” He had reason to be disheartened. His new study reveals an uncomfortable truth: scientific fraud is no longer just the work of a few bad apples. It is organized to the point it’s become industrialized — and growing much faster than legitimate science.
What we are seeing is large networks of editors and authors cooperating to publish fraudulent research at scale. They are exploiting cracks in the system to launder reputations, secure funding, and climb academic ranks.
This isn’t just about the occasional plagiarized paragraph or data fudged to fool reviewers. This is about a vast and resilient system that, in some cases, mimics organized crime. And it’s infiltrating the very core of science.
“These networks are essentially criminal organizations,” Amaral said. “Millions of dollars are involved in these processes.”
A Shadow Industry
The study’s findings stem from a sweeping analysis of over five million scientific papers across more than 70,000 journals. Researchers also examined tens of thousands of retractions, journal editorial records, and even image duplications. What emerged is a disturbing ecosystem: fraudulent “paper mills” manufacturing low-quality studies, brokers selling authorship slots and journal placements, and compromised editors willing to rubber-stamp fake research.
One such paper mill, the Academic Research and Development Association (ARDA), offers a window into how deeply entrenched this problem has become. Notice that they all seem to have legitimate-sounding names. Between 2018 and 2024, ARDA expanded its list of affiliated journals from 14 to 86, many of which were indexed in major academic databases. Some of these journals were later found to be hijacked — illegitimately revived after their original publishers stopped operating. It’s something we’ve seen happen often in our own industry (journalism), as bankrupt legitimate legacy newspapers have been bought by shady venture capital, only to hijack the established brands into spam and affiliate marketing magnets.
What ARDA and similar operations offer isn’t science. It’s superficial credibility and influence, for sale. Clients pay for their names to be placed on prewritten papers, often without contributing any actual research to polish their CVs, which later translates into material advantages.
The System That Allows It
Articles of fraudulent provenance have an apparent growth rategreater than that of the entire scientific enterprise and already far outpacethe scope of science integrity measures currently in use. Credit: PNAS, 2025.
Fraudulent science has always existed, but Richardson’s team found the modern scale unprecedented. Paper mills are now estimated to double their output every 1.5 years. Meanwhile, retractions — the scientific community’s main corrective measure — are doubling every 3.5 years.
In other words, fake science is far outpacing legitimate efforts to catch it. That’s no surprise. Truth seeking has always been expensive, whereas fraud is cheap and fast.
“You either buy into scientific fraud, or you leave science,” the study’s lead author, Reece Richardson, a social scientist at Northwestern University, US, told DW. “This is a situation that tens of thousands of scientists are in.”
The study shows how even some reputable journals have been infiltrated by bad actors. A very small group of editors — fewer than 0.3% at one journal — were found to be responsible for up to 30% of all retracted articles. These editors weren’t catching fraud (one of their main prerogatives); they were enabling it. The analysis revealed that they frequently accepted each other’s submissions, bypassing proper peer review and creating a closed loop of mutual approval. One especially active group at PLOS ONE operated between 2020 and 2023, with many of their accepted papers later retracted for similar reasons: “one of a series of submissions for which we have concerns about authorship, competing interests, and peer review.”
And these aren’t isolated incidents. Similar patterns were identified at Hindawi journals and even in IEEE conference proceedings.
Fraud in the Details
To spot fake science, Richardson’s team looked at things like reused images — telling signs that research data was copied and repackaged. In one network of 2,213 papers with duplicated images, only a third had been retracted.
Other hallmarks of fraud include fast-tracked peer review (under 30 days), odd publication spikes in certain journals, and unnatural authorship patterns — such as unrelated co-authors from across the globe on narrowly focused technical papers.
Many of these fraudulent studies fall into specific subfields, notably areas like micro-RNAs and long noncoding RNAs in cancer biology. The more niche and obscure the research, the better, as it adds another layer of opacity. These subfields saw retraction rates as high as 4%, compared to 0.1% for more established areas like CRISPR.
“You can map out networks of image duplication that are thousands of articles wide,” Richardson said.
Fake Science, Real Consequences
Fraudulent studies mislead scientists, distort meta-analyses, waste public funds, and derail therapeutic development.
Consider the case of Alzheimer’s research. One manipulated paper led to billions in investment and years of follow-up studies before the original research was discredited. During COVID-19, fraudulent studies promoted the use of hydroxychloroquine, which indirectly led to as many as 17,000 fatalities.
“It’s incredible what just one paper can do,” said Anna Abalkina, a research integrity expert at the Free University of Berlin.
Scientific careers are built on publication records. The more papers you publish — and the more citations they accrue — the more funding, jobs, tenure teaching positions, and prestige you attract. In a hypercompetitive system with scarce resources, incentives lean toward quantity over quality.
“If you believe that science is useful and important for humanity, then you have to fight for it,” Amaral said.
The authors argue that existing tools like retractions and journal deindexing, while important, are not enough. Some fake articles remain in databases even after their journals have been deindexed. Others continue to be cited, creating a cascade of misinformation.
Richardson and Amaral advocate for deeper systemic changes: separating conflict-prone tasks like peer review from journals’ business interests, rethinking academic incentives, and moving away from simplistic metrics like citation counts or journal impact factors.
A Looming Threat
The rise of generative AI further complicates matters. If AI models are trained on tainted literature, their outputs — used to generate new research or aid diagnostics — could be compromised from the start. Then there’s the issue of AI-generated science papers. In 2024, a peer-reviewed science journal published a study with an obviously AI-generated diagram showing a cartoon rat with a gigantic penis. Only after the picture made the rounds on social media was the paper retracted.
“We have no clue what’s going to end up in the literature, what’s going to be regarded as scientific fact and what’s going to be used to train future AI models,” Richardson warned.
Some academic publishers, like Springer Nature and Frontiers Media, are starting to issue large-scale retractions — Frontiers recently pulled 122 studies after finding evidence of citation manipulation and undisclosed peer-review collusion. But even these efforts only scratch the surface. Richardson estimates that only 15–25% of fake papers will ever be retracted.
Where Do We Go from Here?
To fix science, experts say the culture must shift. That means funding institutions must reconsider how they measure success. Journals must invest in independent integrity checks. And researchers must be supported in choosing quality over quantity.
“This isn’t about attacking science,” Amaral said. “We are defending it from bad actors.”
The alternative is a slow erosion of trust in one of the most powerful self-correcting tools humanity has ever created. Without reform, future discoveries — and the public good they are meant to serve — may be built on sand.
Compelling graphics at the hyperlink, above.
Get MHF Insights
News and tips for your healthcare freedom.
We never spam you. One-step unsubscribe.














